
Persist AI
Persist AI is a YC Winter 2023 (W23) company. Based in Woodland, CA, USA. Team of 6.
About Persist AI
Summary
Persist AI builds an AI-driven platform that accelerates pharmaceutical drug formulation development for chronic disease treatments such as cancer and diabetes therapies. The platform combines a robotic wet lab with cloud-deployed AI to cut the time needed to develop long-acting injectable and other complex formulations from roughly five years down to two. It replaces the largely manual, trial-and-error process pharma scientists use to select excipients, screen formulations, and compile regulatory-ready documentation.
Business model
Fee-for-service lab work, a cloud AI suite subscription, and custom automation engagements.
Go-to-market
Pharmaceutical and biotech companies are the buyers; they can engage through a self-serve cloud AI suite, a fee-for-service lab offering, or a custom automation build, giving teams multiple entry points depending on their internal capabilities.
From the Y Combinator listing
Developing long-lasting drug formulations 50% faster
It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Woodland, CA, USA
- 6
- Active
- Growth
Founders (2)
- Christopher Shelner
- Karthik Raman
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works